Astrazeneca (AZN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

AstraZeneca (AZN) reported Q2 2025 revenue of $14.46 billion, an 11.7% year-over-year increase, exceeding the Zacks Consensus Estimate by 3.04%, while its $1.09 EPS met analyst expectations. Product-level performance was mixed, highlighted by BioPharmaceuticals-V&I-Europe revenue surging 242.9% year-over-year and strong growth in products like Calquence (+27.3%) and Breztri (+31.6%), though some key oncology and CVRM products such as Imfinzi and Crestor missed estimates. Despite the overall revenue beat, AZN shares have underperformed the S&P 500 over the past month, returning +2.8% compared to the index's +3.6%, and currently hold a Zacks Rank #3 (Hold).

Analysis

AstraZeneca reported a solid Q2 2025 with headline revenue of $14.46 billion, representing an 11.7% year-over-year increase and a 3.04% beat against consensus estimates. However, this top-line strength did not translate to an earnings surprise, as the $1.09 EPS merely met Wall Street expectations. A deeper look into the product segments reveals a mixed performance. The BioPharmaceuticals division showed notable strength, particularly in V&I Europe, which surged 242.9% YoY to $24 million, and in growth products like Lokelma (+32.1% YoY) and Calquence (+27.3% YoY), which all surpassed analyst forecasts. Conversely, the high-value Oncology franchise displayed pockets of weakness in the Established Rest of World region, with key drugs Tagrisso and Imfinzi missing revenue estimates. Imfinzi's performance is a particular concern, with sales declining 4.9% year-over-year and missing estimates significantly. This mixed underlying performance, coupled with the stock's recent 2.8% return underperforming the S&P 500's 3.6% gain, suggests investor caution despite the robust revenue growth.

Key Decisions for Investors

• Investors should weigh the strong consolidated revenue beat against the softer performance within the critical Oncology franchise, where key drugs like Imfinzi and Tagrisso missed regional estimates.
• It is prudent to monitor if the impressive growth from segments like BioPharmaceuticals V&I Europe (+242.9% YoY) and products like Calquence (+27.3% YoY) can sustainably offset the challenges in major oncology assets.
• Given the stock's recent underperformance relative to the market and the in-line EPS, maintaining a neutral or 'Hold' position is justified until there is clearer evidence of a return to broad-based growth across the entire portfolio.